Stock Scorecard



Stock Summary for Astrazeneca plc (AZN) - $78.05 as of 9/17/2025 7:47:19 PM EST

Total Score

10 out of 30

Safety Score

68 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AZN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AZN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AZN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AZN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AZN (68 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 4
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AZN

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial - AstraZeneca ( NASDAQ:AZN ) 9/17/2025 5:20:00 PM
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years 9/17/2025 3:56:00 PM
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off? 9/17/2025 3:22:00 PM
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease ( TNX-4800 ) 9/17/2025 11:00:00 AM
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease ( TNX-4800 ) - Tonix Pharmaceuticals ( NASDAQ:TNXP ) 9/17/2025 11:00:00 AM
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit 9/17/2025 6:55:00 AM
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer 9/16/2025 4:10:00 PM
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer 9/16/2025 3:19:00 PM
What's Going On With AstraZeneca Stock Monday? - AstraZeneca ( NASDAQ:AZN ) , Eli Lilly ( NYSE:LLY ) , Sanofi ( NASDAQ:SNY ) 9/15/2025 3:39:00 PM
3 Emerging Tech Stocks That Could Help Set You Up for Life 9/14/2025 9:15:00 AM

Financial Details for AZN

Company Overview

Ticker AZN
Company Name Astrazeneca plc
Country USA
Description AstraZeneca PLC is a global biopharmaceutical leader headquartered in Cambridge, UK, specializing in the discovery, development, and commercialization of innovative prescription medicines across key therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience, and gastroenterology. With a robust pipeline and a commitment to addressing unmet medical needs, AstraZeneca leverages advanced scientific research and strategic collaborations to drive growth and enhance patient outcomes worldwide. The company is dedicated to sustainable practices and is strategically positioned to thrive in the evolving healthcare landscape.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 6/30/2025
Next Earnings Date 11/6/2025

Stock Price History

Last Day Price 78.05
Price 4 Years Ago 53.38
Last Day Price Updated 9/17/2025 7:47:19 PM EST
Last Day Volume 3,409,475
Average Daily Volume 3,557,585
52-Week High 82.41
52-Week Low 60.83
Last Price to 52 Week Low 28.31%

Valuation Measures

Trailing PE 29.27
Industry PE 24.63
Sector PE 40.64
5-Year Average PE 21.31
Free Cash Flow Ratio 34.23
Industry Free Cash Flow Ratio 35.53
Sector Free Cash Flow Ratio 29.51
Current Ratio Most Recent Quarter 0.86
Total Cash Per Share 2.28
Book Value Per Share Most Recent Quarter 28.85
Price to Book Ratio 5.38
Industry Price to Book Ratio 10.22
Sector Price to Book Ratio 32.14
Price to Sales Ratio Twelve Trailing Months 4.26
Industry Price to Sales Ratio Twelve Trailing Months 3.69
Sector Price to Sales Ratio Twelve Trailing Months 19.15
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 3,100,500,000
Market Capitalization 241,994,025,000
Institutional Ownership 16.74%

Dividends

Ex-Dividend Date 8/8/2025
Previous Dividend Amount 1.0500
Current Dividend Amount 0.5150
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 1.57
Trailing Annual Dividend Yield 1.94%
Forward Annual Dividend Rate 1.03
Forward Annual Dividend Yield 1.28%
5-Year Dividend Payments Count 10
3-Year Average Dividend Yield 2.28%
5-Year Average Dividend Yield 2.37%
1-Year Dividend Growth Rate Percentage 5.39%
3-Year Dividend Growth Rate Percentage 3.89%
5-Year Dividend Growth Rate Percentage 2.82%
All-Time Dividend Growth Rate Percentage 5.87%
Dividend Payout Ratio 58.83%

Income Statement

Quarterly Earnings Growth YOY 27.60%
Annual Earnings Growth 18.14%
Reported EPS 12 Trailing Months 2.65
Reported EPS Past Year 2.04
Reported EPS Prior Year 4.11
Net Income Twelve Trailing Months 8,295,000,000
Net Income Past Year 7,035,000,000
Net Income Prior Year 5,955,000,000
Quarterly Revenue Growth YOY 11.70%
5-Year Revenue Growth 17.27%
Operating Margin Twelve Trailing Months 24.10%

Balance Sheet

Total Cash Most Recent Quarter 7,058,000,000
Total Cash Past Year 5,488,000,000
Total Cash Prior Year 5,840,000,000
Net Cash Position Most Recent Quarter -17,656,000,000
Net Cash Position Past Year -21,018,000,000
Long Term Debt Past Year 26,506,000,000
Long Term Debt Prior Year 22,365,000,000
Total Debt Most Recent Quarter 24,714,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.64
Total Stockholder Equity Past Year 40,786,000,000
Total Stockholder Equity Prior Year 39,143,000,000
Total Stockholder Equity Most Recent Quarter 44,719,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 8,724,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.81
Free Cash Flow Past Year 7,275,000,000
Free Cash Flow Prior Year 6,567,000,000

Options

Put/Call Ratio 0.24
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.24
MACD Signal 1.71
20-Day Bollinger Lower Band 64.21
20-Day Bollinger Middle Band 73.46
20-Day Bollinger Upper Band 82.71
Beta 0.16
RSI 46.36
50-Day SMA 70.84
150-Day SMA 68.77
200-Day SMA 65.85

System

Modified 9/17/2025 6:17:55 PM EST